468 related articles for article (PubMed ID: 24444353)
1. Loss of intrahepatic HBsAg expression predicts sustained response to peginterferon and is reflected by pronounced serum HBsAg decline.
Arends P; Rijckborst V; Zondervan PE; Buster E; Cakaloglu Y; Ferenci P; Tabak F; Akarca US; Simon K; Sonneveld MJ; Hansen BE; Janssen HL
J Viral Hepat; 2014 Dec; 21(12):897-904. PubMed ID: 24444353
[TBL] [Abstract][Full Text] [Related]
2. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
[TBL] [Abstract][Full Text] [Related]
3. Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma.
Safaie P; Poongkunran M; Kuang PP; Javaid A; Jacobs C; Pohlmann R; Nasser I; Lau DT
World J Gastroenterol; 2016 Mar; 22(12):3404-11. PubMed ID: 27022222
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir.
Reijnders JG; Rijckborst V; Sonneveld MJ; Scherbeijn SM; Boucher CA; Hansen BE; Janssen HL
J Hepatol; 2011 Mar; 54(3):449-54. PubMed ID: 21112655
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.
Chuaypen N; Sriprapun M; Praianantathavorn K; Payungporn S; Wisedopas N; Poovorawan Y; Tangkijvanich P
J Med Virol; 2017 Jan; 89(1):130-138. PubMed ID: 27307409
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
[TBL] [Abstract][Full Text] [Related]
7. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
8. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.
Thompson AJ; Nguyen T; Iser D; Ayres A; Jackson K; Littlejohn M; Slavin J; Bowden S; Gane EJ; Abbott W; Lau GK; Lewin SR; Visvanathan K; Desmond PV; Locarnini SA
Hepatology; 2010 Jun; 51(6):1933-44. PubMed ID: 20512987
[TBL] [Abstract][Full Text] [Related]
9. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
Martinot-Peignoux M; Lapalus M; Laouénan C; Lada O; Netto-Cardoso AC; Boyer N; Ripault MP; Carvalho-Filho R; Asselah T; Marcellin P
J Clin Virol; 2013 Oct; 58(2):401-7. PubMed ID: 24004660
[TBL] [Abstract][Full Text] [Related]
10. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.
Li J; Sun X; Fang J; Wang C; Han G; Ren W
Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):635-643. PubMed ID: 28438570
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.
Manesis EK; Papatheodoridis GV; Tiniakos DG; Hadziyannis ES; Agelopoulou OP; Syminelaki T; Papaioannou C; Nastos T; Karayiannis P
J Hepatol; 2011 Jul; 55(1):61-8. PubMed ID: 21145875
[TBL] [Abstract][Full Text] [Related]
12. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
[TBL] [Abstract][Full Text] [Related]
13. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B.
Chuaypen N; Posuwan N; Payungporn S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
Liver Int; 2016 Jun; 36(6):827-36. PubMed ID: 26678018
[TBL] [Abstract][Full Text] [Related]
14. Correlation between intrahepatic hepatitis B virus cccDNA levels and other activity markers in patients with HBeAg-negative chronic hepatitis B infection.
Guner R; Karahocagil M; Buyukberber M; Kandemir O; Ural O; Usluer G; Inan D; Koksal I; Baykam N; Hizel K; Yamazhan T; Esen S; Tasyaran MA
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1185-91. PubMed ID: 21934508
[TBL] [Abstract][Full Text] [Related]
15. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
[TBL] [Abstract][Full Text] [Related]
16. The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B.
Demirören K; Kocamaz H; Doğan Y
Turk J Gastroenterol; 2015 Jan; 26(1):36-41. PubMed ID: 25698269
[TBL] [Abstract][Full Text] [Related]
17. Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients.
Lin LY; Wong VW; Zhou HJ; Chan HY; Gui HL; Guo SM; Wang H; Huang L; Bao SS; Xie Q; Chan HL
J Med Virol; 2010 Sep; 82(9):1494-500. PubMed ID: 20648602
[TBL] [Abstract][Full Text] [Related]
18. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.
Chan HL; Wong VW; Tse AM; Tse CH; Chim AM; Chan HY; Wong GL; Sung JJ
Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1462-8. PubMed ID: 18054753
[TBL] [Abstract][Full Text] [Related]
19. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy.
Papatheodoridis G; Goulis J; Manolakopoulos S; Margariti A; Exarchos X; Kokkonis G; Hadziyiannis E; Papaioannou C; Manesis E; Pectasides D; Akriviadis E
J Hepatol; 2014 Jan; 60(1):62-8. PubMed ID: 24012614
[TBL] [Abstract][Full Text] [Related]
20. Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.
Lee MH; Lee DM; Kim SS; Cheong JY; Cho SW
J Med Virol; 2011 Jul; 83(7):1178-86. PubMed ID: 21567421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
